Novo Nordisk Trades at a Discount While Volumes Compound

Novo Nordisk (NVO) is a Danish pharmaceutical company operating in two segments, Obesity and Diabetes care, and Rare disease. It holds a 59.6% branded volume share of the global obesity market and a 30.1% value share of global diabetes, and its portfolio is anchored on a single molecule, semaglutide, marketed as Ozempic, Rybelsus and Wegovy.